Bloomage Biotech(SH:688363) Zhong Guo Zheng Quan Bao·2025-11-23 20:06Core Viewpoint - The company is actively adjusting its operations and organizational structure to enhance its long-term competitiveness in the synthetic biology sector, focusing on high-quality development paths in the biomanufacturing industry [1][2]. Group 1: Strategic Adjustments and Financial Performance - The company has seen a profit growth trend, with a net profit of 0.32 billion yuan in Q3 2025, representing a year-on-year increase of 55.63%, and revenue of 9.03 billion yuan, indicating continuous improvement over two consecutive quarters [1]. - The decline in revenue during the first three quarters was primarily due to a decrease in skin science innovation conversion business, which is viewed as a temporary outcome of the ongoing adjustments [2]. - The company has reduced ineffective spending and adjusted its evaluation system, resulting in a sales expense ratio of 34.26%, the lowest in five years, while still achieving approximately 55% profit growth year-on-year [3]. Group 2: Focus on C-end Business and Ecosystem Development - The C-end business is a key focus of the company's adjustments, emphasizing the need to accurately define brand positioning and target demographics to create real value for consumers [2]. - The company is accelerating the construction of an ecosystem that fosters mutual growth with users, platforms, and partners to solidify the foundation for C-end business development [2]. Group 3: Synthetic Biology and Technological Innovation - The company is centered on synthetic biology, particularly in glycomics, aiming to provide systematic solutions for delaying aging [4]. - The synthetic biology system is supported by two core platforms: a biocatalyst library and a pilot transformation platform, which facilitate rapid new molecule screening and scale-up verification [4][8]. - The company has achieved significant technological advancements, such as the precise synthesis of heparin through a fully enzymatic method, moving towards "green biomanufacturing" [4]. Group 4: Pilot Testing and AI Integration - The pilot platform is crucial for connecting research, validation, and transformation, serving as a key facility for technology maturity verification and data model accumulation [8]. - The company has invested in a synthetic biology pilot transformation platform equipped with fermentation systems and production lines to support core functions like mechanism verification and process standardization [7][8]. - The open and shared mechanism of the pilot platform is becoming an essential part of the national innovation system, supporting both the company's growth and the broader industry ecosystem [8][9].